Virtu KCG Holdings’s Outlook Therapeutics OTLK Stock Holding History

Virtu KCG Holdings’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-63	Closed	-$43K	–	3685
2016 Q3	$43K	Buy	+63	New	+$40K	﹤0.01%	2816

Other funds holding OTLK

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtu KCG Holdings's OTLK Position: Q4 2016 in Review

Virtu KCG Holdings sold out of Outlook Therapeutics (OTLK) in Q4 2016, closing a stake of 63 shares — an estimated $43K sold.

Virtu KCG Holdings first reported a position in OTLK in Q3 2016 and held it in 1 quarter. The position peaked at $43K in Q3 2016. 15 funds tracked by Wall St. Rank hold OTLK as of Q4 2016.

Virtu KCG Holdings reported no remaining Outlook Therapeutics position as of Q4 2016 after selling out during the quarter.
Virtu KCG Holdings sold 63 Outlook Therapeutics shares in Q4 2016, an estimated $43K.
Virtu KCG Holdings first reported a position in Outlook Therapeutics in Q3 2016 and held it in 1 quarter.
Virtu KCG Holdings's Outlook Therapeutics position peaked at $43K in Q3 2016.
15 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2016.

Based on Virtu KCG Holdings's 13F filing for Q4 2016, filed 10 Feb 2017.